Cross-Market Price Comparison
| Other Listed Market | Shanghai (SSE) — 上海医药 |
|---|---|
| Other Market Stock Code | 601607 |
| H-Share Offer Price | To be extracted |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | 上海醫藥集團股份有限公司 － Ｈ股 |
|---|---|
| Stock Code | 02607 |
| Company Full Name | 上海醫藥集團股份有限公司 － Ｈ股 |
| Industry | 醫療保健 |
| Principal Activities | 主要在中國從事制藥業務、醫藥分銷及供應鏈解決方案和藥品零售。 |
| Listing Date | 2011-05-20 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市太倉路200號上海醫藥大廈 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.sphchina.com |
| Share Registrar | |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 23.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 28.0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 1,145,772,600 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 23.0 |
|---|---|
| First Day Open | HK$ 23.25 |
| First Day Change | -48.22% |
| First Day Volume | 81571700.0 |
| First Day Turnover | 1879790000.0 |
Use of Proceeds
| Use of Proceeds | 1、所得款項凈額約40%（或約5,909百萬港元）預期將用于擴大及加強我們的分銷網絡及整合現有分銷網絡； 2、所得款項凈額約30%（或約4,432百萬港元）預期將用于戰略性收購中國國內及國際醫藥制造業務； 3、所得款項凈額約10%（或約1,477百萬港元）預期將用于產品研發平臺的投資，以進一步加強我們的產品組合及在研產品； 4、所得款項凈額約10%（或約1,477百萬港元）預期將用于信息技術系統及平臺的投資； 5、所得款項凈額剩余約10%（或約1,477百萬港元）預期將用于我們的營運資金需求及一般企業用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (4)
高盛（亚洲）有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
德意志银行香港分行
Credit Suisse (Hong Kong) Limited CE AAO017
Overall Coordinators (3)
高盛（亚洲）有限责任公司 CE ACC536
德意志银行香港分行
Credit Suisse (Hong Kong) Limited CE AAO017
Joint Bookrunners (4)
高盛（亚洲）有限责任公司 CE ACC536
德意志银行香港分行
Credit Suisse (Hong Kong) Limited CE AAO017
中国国际金融香港证券有限公司 CE AEN894
Joint Lead Managers (3)
高盛（亚洲）有限责任公司 CE ACC536
德意志银行香港分行
Credit Suisse (Hong Kong) Limited CE AAO017
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | GuoLine Capital Limited | 388,483,800 HKD | — | 2.54% | — | 6 months | 2011-11-20 |
| 2 | 淡马锡控股(私人)有限公司 | 2,330,909,700 HKD | — | 15.26% | — | 6 months | 2011-11-20 |
| 3 | 国浩管理有限公司 | 776,969,900 HKD | — | 5.09% | — | 6 months | 2011-11-20 |
| 4 | 美国辉瑞(香港)有限公司 | 388,483,800 HKD | — | 2.54% | — | 6 months | 2011-11-20 |
| 5 | 中银集团投资有限公司 | 388,483,800 HKD | — | 2.54% | — | 6 months | 2011-11-20 |
Directors & Management
| Chairman | 楊秋華 |
|---|---|
| Company Secretary | 鐘濤;黃沛翹 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 上海實業(集團)有限公司(33.44%);貝萊德(1.76%) |
|---|
